STTK - Shattuck Labs Inc logo

STTK

Shattuck Labs Inc

Shattuck Labs develops antibody therapies for inflammatory and immune-mediated diseases, focusing on treatments like SL-325 for inflammatory bowel disease and other conditions, with several preclinical and clinical programs targeting various pathways.

⚕️ Healthcare NASDAQ Listed 2020 $ USD
$1,000 invested 5 years ago $364today

Score Overview

1 Year
Score
Net Growth-2.18%
Net TrendShrank
Net Income Consistency
Rev Growth0.00%
Rev TrendShrank
Revenue Consistency
5 Years
Score4.1
Net Growth-10.90%
Net Trend60%
Net Income Consistency
Rev Growth-96.67%
Rev Trend40%
Revenue Consistency
All Time
Score
Net Growth-40.74%
Net Trend50%
Net Income Consistency
Rev Growth-89.93%
Rev Trend50%
Revenue Consistency

See the full market ranking →

Shattuck Labs Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 9M to $ 1M and net income went from -$ 35M to -$ 48M. Revenue increased in 2 of those 5 years; net income in 3.

Shattuck Labs Inc currently holds a 5-year HDB Score of 4.1 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 7.49
1 Year2025-08-12
$ 0.769x
5 Years2021-08-12
$ 20.58-63.61%
All Time2020-10-09
$ 19.35-61.29%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 1M-$ 49M$ 90M
2025$ 1M-$ 48M$ 78M
2024$ 5M-$ 75M$ 72M
2023$ 1M-$ 87M$ 130M
2022$ 652K-$ 100M$ 161M
2021$ 30M-$ 44M$ 268M
IPO2020$ 9M-$ 35M$ 335M

Explore beyond STTK

You're looking at Shattuck Labs Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies